The objectives of the Cancer Research Informatics Core (CRIC) are: 1. To maintain a cost effective research informatics resource for Cancer Center investigators. 2. To coordinate with the Biostatistics Core Resource, the Translational Pathology Core, the Microarray Core Facility and the Clinical Investigations Support Office (CISO) all research data management and computing requirements for Cancer Center investigators. 3. To safeguard confidentiality/privacy of the patient specific clinical information. Over the last 12-18 months, the NCI has identified the need to modernize its processes incorporating the new tools of electronic commerce. This undertaking is being called the Cancer Informatics Infrastructure (CII). The goals of this program include: the creation of an enterprise for both basic and clinical research in cancer; the use of standards to insure the interoperability of information systems; and, the simplification of the clinical trials process from inception to publication, in a secure and user specific way. A fundamental priority in this process is the security and confidentiality of patient specific information. These goals on a national scale are highly compatible with the goals of the CRIC at the local level, i.e., to provide comprehensive informatics support to the Center's research community. This is reflected by the central cancer research database that has been created along with a number of disease-specific databases that have also been established. The focus of this Core resource is to build on this existing base, to design and develop additional disease- specific databases and modify those currently existing, when required, to support the varied research efforts of the Cancer Center's investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-26S1
Application #
6504901
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-04-06
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications